Information Provided By:
Fly News Breaks for February 27, 2020
Feb 27, 2020 | 11:47 EDT
JPMorgan analyst Cory Kasimov raised the firm's price target on Moderna to $32 from $24 and keeps an Overweight rating on the shares. Even though he tells investors that Moderna's Q4 earnings report and associated call were "relatively uneventful" and the ultimate commercial opportunity for its Covid-19 vaccine candidate is "unlikely to be substantial," Kasimov also believes the rapid turnaround illustrates the potential power of the company's platform and he expects near-to-medium term progress to "gradually inform the possibly disruptive capabilities of this company."
News For MRNA From the Last 2 Days
Nov 23, 2020 | 09:54 EST
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Moderna (MRNA) initiated with an Equal Weight at Wells Fargo. 2. Biodesix (BDSX) initiated with a Buy at Canaccord. 3. MediaAlpha (MAX) initiated with an Outperform at William Blair. 4. G-III Apparel (GIII) initiated with a Neutral at UBS. 5. Leslie's (LESL) initiated with a Neutral at Goldman Sachs, Guggenheim and BofA and initiated with an Equal Weight at Morgan Stanley. The company was initiated with an Outperform at Telsey Advisory, Baird and William Blair as well. Additionally, Leslie's initiated with an Overweight at Piper Sandler. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.